GR3027 reverses neurosteroid-induced, GABAA receptor-mediated inhibition of brain function: a human challenge study
About: This article is published in Journal of Hepatology.The article was published on 2017-01-01. It has received 1 citations till now. The article focuses on the topics: GABAA receptor & Neuroactive steroid.
Citations
More filters
Patent•
31 May 2019TL;DR: In this article, a novel pharmaceutical formulation comprising 3α-ethynyl-3β- hydroxyandrostan-17-one oxime in an amount of 0.1-10 % by weight of the total weight of a composition was presented for the treatment of hypersomnia and hepathic encephalopathy.
Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β- hydroxyandrostan-17-one oxime in an amount of 0.1-10 % by weight of the total weight of the composition; and a vehicle comprising (a) 45-100 % of a monoester; (b) optionally up to 51 % of a diester; and (c) optionally up to about 10 % of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.